May 9th 2024
Developers will work with investigators of the phase 3 KEYNOTE-B21 trial to share their findings with the scientific community.
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Commentary (Horowitz): Laparoscopy in Gynecologic Malignancies
June 1st 1999Laparoscopy dates back to 1901 when Kelling inspected a dog’s abdominal cavity with a cystoscope introduced transcutaneously. This technique was subsequently applied to humans in 1923.[1] Jacobaeus, in 1910, developed instruments
Commentary (Spirtos/Eisenkop): Laparoscopy in Gynecologic Malignancies
June 1st 1999Minimally invasive surgery is simply the use of small incisions with specialized equipment to accomplish surgical objectives that would otherwise be completed through larger incisions with conventional equipment. A priority of gyne-cologic oncologists
Chemo Improves Survival in High-Risk Cervical Cancer
June 1st 1999SAN FRANCISCO-A major intergroup phase III study reported at the 30th Annual Meeting of the Society of Gynecologic Oncologists has shown that adding chemotherapy to radiation therapy improves the overall survival rate for women with high-risk early-stage cervical cancer. William A. Peters III, MD, of the Puget Sound Oncology Consortium, Seattle, reported the results on behalf of researchers from the Southwest Oncology Group, Gynecologic Oncology Group, and Radiation Therapy Oncology Group.
Chemotherapy Plus Radiation Improves Survival in Patients With Cervical Cancer
March 1st 1999The National Cancer Institute (NCI) recently sent a clinical announcement to thousands of physicians stating that strong consideration should be given to adding chemotherapy to radiation therapy in the treatment of invasive cervical cancer.
US Clinical Trial of New Cervical Cancer Detection System to Begin
October 1st 1998NetMed, Inc., a developer and marketer of medical and health-related technologies, announced the commencement of a multicenter US clinical trial of the PAPNET cervical cancer detection system as a primary screening test for Pap smears. The
Practice Guidelines: Uterine Corpus—Endometrial Cancer
January 1st 1998Endometrial cancer is the most common type of female genital cancer in the United States, with an estimated 32,000 new cases and 5,600 deaths per year. During the first half of the 20th century, the incidence of cervical cancer was greater than
Researchers Report Conflicting Data on Cervical Cancer in AIDS
July 1st 1997BETHESDA, Md--A review of 10 years' experience with HIV-infected patients treated at University Hospital, Newark, NJ, revealed significantly elevated levels of several types of cancers, but a surprising dearth of invasive cervical cancers, which prompted the study's lead author to suggest dropping cervical cancer from the list of AIDS-associated malignancies.
Summary of the NIH Consensus Development Conference on Cervical Cancer
May 1st 1997Carcinoma of the cervix is one of the most common malignancies in women, accounting for 15,700 new cases and 4,900 deaths in the United States each year. Worldwide, cervical cancer is second only to breast cancer as the most common
'More May Be Less' in Metastatic Cervical Cancer
February 1st 1997VIENNA--A new study from the EORTC Gynecologic Cancer Cooperative Group (GCCG) has challenged the assumption that aggressive combination chemotherapy is worthwhile in chemotherapy-naïve women with metastatic squamous cell cancer of the cervix.
Breast and Cervical Cancer Early Detection Program to Expand
December 1st 1996WASHINGTON--For the first time since its inception in 1991, funds from the Breast and Cervical Cancer Early Detection Program will flow to all 50 states in fiscal 1997, the Department of Health and Human Services announced.
Benefits of Tamoxifen Outweigh Endometrial Cancer Risk
An expert panel of nine international cancer researchers and practicing oncologists met in Boston to discuss the past, present, and future uses of antiestrogens in the treatment of breast cancer. The first article in this series, based on the symposium presentations, focused on the optimal duration of tamoxifen use (October 1996). This month, the panel explores the noncancer benefits of tamoxifen, as well as the potential risk of endometrial cancer. The symposium was sponsored by Zeneca Pharmaceuticals.
Changing Concepts in the Management of Endometrial Cancer
July 1st 1996In their comprehensive review of changing concepts in the management of endometrial cancer, Drs. Karasek and Faul highlight the contemporary approach to the management of patients with endometrial adenocarcinoma. The authors stress the evolution
Changing Concepts in the Management of Endometrial Cancer
July 1st 1996The authors present the major issues and controversies surrounding the treatment of endometrial cancer. A variety of therapeutic approaches have been used in the past, including surgery alone, preoperative radiation and surgery, surgery and
DFMO Shows Potential in the Prevention of Cervical Cancer
June 1st 1996NEW ORLEANS--In a phase I trial from M.D. Anderson Cancer Center, the chemopreventive agent difluorometh-ylornithine (DFMO) produced significant regression of cervical intraepithelial neoplasia (CIN) grade 3, Michele Follen Mitchell, MD, reported at the Society of Gynecologic Oncologists meeting.
Cervical Cancer: Behavioral Changes Could Save Most Women
June 1st 1996Cervical cancer's slow, noticeable growth makes it "an ideal disease" for screening, but poor choices--like not getting a Pap smear or having unprotected sex as young adults--give the disease a disastrous head start, a University of Wisconsin Medical
No Increased Ovarian, Endometrial Cancer Risk With Short-Term Tamoxifen Therapy
October 1st 1995SEATTLE-A group of breast cancer patients treated with tamoxifen (Nolvadex) outside of clinical trials had up to a 60% reduction in their risk of developing cancer in the contralateral breast and no increased risk of ovarian or endometrial cancer, report Linda S. Cook, PhD, and her colleagues at the Fred Hutchinson Cancer Research Center.